Notably, several CD33 × CD3 BiTEs have shown promising results with an acceptable toxicity profile in clinical trials for R/R AML (AMG 330,232,233 AMG 673,234 GEM333, JNJ-67571244, and SAR440234) (Fig. 4). This evidence concerns the gene CD33 and acute myeloid leukemia.